# RxAnte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rxante

- Industry: Healthcare IT
- Headquarters: Portland, US
- Website: www.rxante.com
- Latest round: Series A (Sep 12, 2012)
- Investors on record: 2

## About

RxAnte, Inc. is a healthcare technology company focused on enhancing Pharmacy Care Management (PCM) solutions to optimize medication use and improve patient health outcomes across healthcare systems.RxAnte, Inc. was founded in 2011 and is headquartered in Portland, US. The company specializes in Pharmacy Care Management, providing tailored medication management solutions. Loren Lidsky is the founder, while Josh Benner serves as the CEO. RxAnte has participated in three funding deals, with the most recent funding occurring on December 21, 2022, through a USD 25 million debt financing from Trinity Capital Investment.RxAnte specializes in providing innovative Pharmacy Care Management (PCM) solutions that aim to optimize medication use and improve health outcomes. The company's core offerings include a value-based pharmacy service called Mosaic, which targets at-risk members of health plans and providers to deliver tailored medication management strategies. RxAnte configures its patented analytics and software to the unique demographics of its client populations, ensuring that interventions are personalized and effective. The services are designed to enhance care quality while reducing healthcare costs, making them particularly valuable for health plans, providers, and pharmacies across various geographical markets, including the United States and potentially other regions with established healthcare systems. RxAnte’s clientele includes health plans, value-based providers, and pharmacies, all seeking to improve medication adherence and quality of care for their members.RxAnte generates revenue through its suite of PCM services, primarily via B2B arrangements with health plans and providers. The transactions typically occur as subscription-based partnerships, where clients pay for ongoing access to RxAnte's analytics platform and support services. This structure allows health plans to implement comprehensive medication management strategies while benefiting from continuous performance measurement. Key services, particularly the Mosaic pharmacy service and RxEFFECT® adherence workflow solution, are integral to these agreements, as they offer significant value in terms of quality improvement and cost reduction. The financial model emphasizes aligning the services provided with the performance outcomes achieved for clients, fostering a mutually beneficial relationship.RxAnte plans to utilize the recent USD 25 million debt financing from December 2022 to support the development of new products and expand its market reach. The company is currently focused on enhancing its existing PCM solutions and launching new features aimed at improving medication management. Additionally, RxAnte is exploring opportunities to enter new geographic regions, aiming to establish a presence in markets beyond the United States by 2024. In January 2026, Primus invested RxAnte, Inc. Financial terms were not disclosed.

## Funding rounds

- Series A, Sep 12, 2012 — Aberdare Ventures, West Health Investment Fund

## Investors

- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series A
- West Health Investment Fund — Series A